Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agenc...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2023-12, Vol.19 (1), p.2168952-2168952 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2168952 |
|---|---|
| container_issue | 1 |
| container_start_page | 2168952 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 19 |
| creator | Giannelos, Nikolaos Ng, Cheryl Curran, Desmond |
| description | The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agency websites to identify and collect data from CE studies comparing RZV to zoster vaccine live (ZVL) or to no vaccination. Study characteristics, inputs, and outputs were collected. The overall CE of RZV was assessed. RZV vaccination against HZ is cost-effective in 15 out of 18 studies included in the present review. Varying incremental cost-effectiveness ratios (ICERs) observed may be associated with different assumptions on the duration of protection of RZV, as well as different combinations of structural and disease-related study (model) inputs driving the estimation of ICERs.
What is the context?
* Herpes zoster, also known as shingles, may cause painful rashes and skin alterations.
* Chronic pain, also referred to as post-herpetic neuralgia, may persist for months or even years after the initial rash.
* The disease is caused by reactivation of the varicella zoster virus.
* The recombinant zoster vaccine (RZV) and the zoster vaccine live (ZVL) are approved for the prevention of herpes zoster and post-herpetic neuralgia.
* We reviewed published evidence from the past 5 years on RZV.
What is new?
* Out of 18 selected studies, RZV vaccination against herpes zoster and post-herpetic neuralgia is cost-effective in 15.
* In the 15 studies establishing RZV cost-effectiveness, RZV is always cost-effective or frequently cost-saving in direct comparisons to ZVL, when applicable.
* RZV was found cost-saving in several immune-compromised populations.
What is the impact?
* The overview of the currently available body of evidence related to cost-effectiveness of RZV may help informing decision makers about the value of vaccination against herpes zoster. |
| doi_str_mv | 10.1080/21645515.2023.2168952 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_miscellaneous_2786813548</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_04e618451d634eb090eea6c65e94dcbd</doaj_id><sourcerecordid>2786813548</sourcerecordid><originalsourceid>FETCH-LOGICAL-c535t-d5f161c27c0bc8135a160daf42b8ae5686fa27c4ef18b314b309148fce93f8d13</originalsourceid><addsrcrecordid>eNp9kcFuEzEQhlcIRKvSRwD5WA4b7F3b8XKBKipQqRISAoS4WLP2OHG1awfbSVWeng1JI3rBF3tmvvlnrL-qXjI6Y1TRNw2TXAgmZg1t2tkUqU40T6rTXb4Wgv94enwzcVKd53xLpzOnDZfyeXXSyo7JhtPTaljEXGp0Dk3xWwyYM4mOlBWShCaOvQ8QCvk9UZjIFozxAcnFl5_fXxNYgg-5kBWmNeYD85ZcBrJZWyhoiUm-eAPDpLX1ePeieuZgyHh-uM-qbx-uvi4-1TefP14vLm9qI1pRaisck8w0c0N7o1grgElqwfGmV4BCKulgKnJ0TPUt431LO8aVM9i1TlnWnlXXe10b4Vavkx8h3esIXv9NxLTUkKbFBtSUo2SKC2Zly7GnHUUEaaTAjlvT20nr3V5rvelHtAZDSTA8En1cCX6ll3GrGaWCM7Xb5uKgkOKvDeaiR58NDgMEjJusm7mSu19yNaFij5oUc07ojnMY1Tvn9YPzeue8Pjg_9b36d8lj14PPE_B-D_jgYhrhLqbB6gL3Q0wuQTA-6_b_M_4A1ce-zA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2786813548</pqid></control><display><type>article</type><title>Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><creator>Giannelos, Nikolaos ; Ng, Cheryl ; Curran, Desmond</creator><creatorcontrib>Giannelos, Nikolaos ; Ng, Cheryl ; Curran, Desmond</creatorcontrib><description>The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agency websites to identify and collect data from CE studies comparing RZV to zoster vaccine live (ZVL) or to no vaccination. Study characteristics, inputs, and outputs were collected. The overall CE of RZV was assessed. RZV vaccination against HZ is cost-effective in 15 out of 18 studies included in the present review. Varying incremental cost-effectiveness ratios (ICERs) observed may be associated with different assumptions on the duration of protection of RZV, as well as different combinations of structural and disease-related study (model) inputs driving the estimation of ICERs.
What is the context?
* Herpes zoster, also known as shingles, may cause painful rashes and skin alterations.
* Chronic pain, also referred to as post-herpetic neuralgia, may persist for months or even years after the initial rash.
* The disease is caused by reactivation of the varicella zoster virus.
* The recombinant zoster vaccine (RZV) and the zoster vaccine live (ZVL) are approved for the prevention of herpes zoster and post-herpetic neuralgia.
* We reviewed published evidence from the past 5 years on RZV.
What is new?
* Out of 18 selected studies, RZV vaccination against herpes zoster and post-herpetic neuralgia is cost-effective in 15.
* In the 15 studies establishing RZV cost-effectiveness, RZV is always cost-effective or frequently cost-saving in direct comparisons to ZVL, when applicable.
* RZV was found cost-saving in several immune-compromised populations.
What is the impact?
* The overview of the currently available body of evidence related to cost-effectiveness of RZV may help informing decision makers about the value of vaccination against herpes zoster.</description><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2023.2168952</identifier><identifier>PMID: 36916240</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Cost-Benefit Analysis ; cost-effectiveness ; Herpes zoster ; Herpes Zoster - prevention & control ; Herpes Zoster Vaccine ; Herpesvirus 3, Human ; Humans ; Licensed Vaccines – Review ; Neuralgia, Postherpetic - prevention & control ; older adults ; recombinant zoster vaccine ; Review ; Vaccination ; Vaccines, Synthetic</subject><ispartof>Human vaccines & immunotherapeutics, 2023-12, Vol.19 (1), p.2168952-2168952</ispartof><rights>2023 GlaxoSmithKline Biologicals SA. Published with license by Taylor & Francis Group, LLC. 2023</rights><rights>2023 GlaxoSmithKline Biologicals SA. Published with license by Taylor & Francis Group, LLC. 2023 GlaxoSmithKline Biologicals SA</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c535t-d5f161c27c0bc8135a160daf42b8ae5686fa27c4ef18b314b309148fce93f8d13</citedby><cites>FETCH-LOGICAL-c535t-d5f161c27c0bc8135a160daf42b8ae5686fa27c4ef18b314b309148fce93f8d13</cites><orcidid>0000-0002-7423-0111 ; 0000-0002-1707-2305 ; 0000-0001-9130-4744</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2168952$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/21645515.2023.2168952$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,864,885,2102,27502,27924,27925,59143,59144</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36916240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giannelos, Nikolaos</creatorcontrib><creatorcontrib>Ng, Cheryl</creatorcontrib><creatorcontrib>Curran, Desmond</creatorcontrib><title>Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agency websites to identify and collect data from CE studies comparing RZV to zoster vaccine live (ZVL) or to no vaccination. Study characteristics, inputs, and outputs were collected. The overall CE of RZV was assessed. RZV vaccination against HZ is cost-effective in 15 out of 18 studies included in the present review. Varying incremental cost-effectiveness ratios (ICERs) observed may be associated with different assumptions on the duration of protection of RZV, as well as different combinations of structural and disease-related study (model) inputs driving the estimation of ICERs.
What is the context?
* Herpes zoster, also known as shingles, may cause painful rashes and skin alterations.
* Chronic pain, also referred to as post-herpetic neuralgia, may persist for months or even years after the initial rash.
* The disease is caused by reactivation of the varicella zoster virus.
* The recombinant zoster vaccine (RZV) and the zoster vaccine live (ZVL) are approved for the prevention of herpes zoster and post-herpetic neuralgia.
* We reviewed published evidence from the past 5 years on RZV.
What is new?
* Out of 18 selected studies, RZV vaccination against herpes zoster and post-herpetic neuralgia is cost-effective in 15.
* In the 15 studies establishing RZV cost-effectiveness, RZV is always cost-effective or frequently cost-saving in direct comparisons to ZVL, when applicable.
* RZV was found cost-saving in several immune-compromised populations.
What is the impact?
* The overview of the currently available body of evidence related to cost-effectiveness of RZV may help informing decision makers about the value of vaccination against herpes zoster.</description><subject>Cost-Benefit Analysis</subject><subject>cost-effectiveness</subject><subject>Herpes zoster</subject><subject>Herpes Zoster - prevention & control</subject><subject>Herpes Zoster Vaccine</subject><subject>Herpesvirus 3, Human</subject><subject>Humans</subject><subject>Licensed Vaccines – Review</subject><subject>Neuralgia, Postherpetic - prevention & control</subject><subject>older adults</subject><subject>recombinant zoster vaccine</subject><subject>Review</subject><subject>Vaccination</subject><subject>Vaccines, Synthetic</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kcFuEzEQhlcIRKvSRwD5WA4b7F3b8XKBKipQqRISAoS4WLP2OHG1awfbSVWeng1JI3rBF3tmvvlnrL-qXjI6Y1TRNw2TXAgmZg1t2tkUqU40T6rTXb4Wgv94enwzcVKd53xLpzOnDZfyeXXSyo7JhtPTaljEXGp0Dk3xWwyYM4mOlBWShCaOvQ8QCvk9UZjIFozxAcnFl5_fXxNYgg-5kBWmNeYD85ZcBrJZWyhoiUm-eAPDpLX1ePeieuZgyHh-uM-qbx-uvi4-1TefP14vLm9qI1pRaisck8w0c0N7o1grgElqwfGmV4BCKulgKnJ0TPUt431LO8aVM9i1TlnWnlXXe10b4Vavkx8h3esIXv9NxLTUkKbFBtSUo2SKC2Zly7GnHUUEaaTAjlvT20nr3V5rvelHtAZDSTA8En1cCX6ll3GrGaWCM7Xb5uKgkOKvDeaiR58NDgMEjJusm7mSu19yNaFij5oUc07ojnMY1Tvn9YPzeue8Pjg_9b36d8lj14PPE_B-D_jgYhrhLqbB6gL3Q0wuQTA-6_b_M_4A1ce-zA</recordid><startdate>20231231</startdate><enddate>20231231</enddate><creator>Giannelos, Nikolaos</creator><creator>Ng, Cheryl</creator><creator>Curran, Desmond</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7423-0111</orcidid><orcidid>https://orcid.org/0000-0002-1707-2305</orcidid><orcidid>https://orcid.org/0000-0001-9130-4744</orcidid></search><sort><creationdate>20231231</creationdate><title>Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review</title><author>Giannelos, Nikolaos ; Ng, Cheryl ; Curran, Desmond</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c535t-d5f161c27c0bc8135a160daf42b8ae5686fa27c4ef18b314b309148fce93f8d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cost-Benefit Analysis</topic><topic>cost-effectiveness</topic><topic>Herpes zoster</topic><topic>Herpes Zoster - prevention & control</topic><topic>Herpes Zoster Vaccine</topic><topic>Herpesvirus 3, Human</topic><topic>Humans</topic><topic>Licensed Vaccines – Review</topic><topic>Neuralgia, Postherpetic - prevention & control</topic><topic>older adults</topic><topic>recombinant zoster vaccine</topic><topic>Review</topic><topic>Vaccination</topic><topic>Vaccines, Synthetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giannelos, Nikolaos</creatorcontrib><creatorcontrib>Ng, Cheryl</creatorcontrib><creatorcontrib>Curran, Desmond</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giannelos, Nikolaos</au><au>Ng, Cheryl</au><au>Curran, Desmond</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2023-12-31</date><risdate>2023</risdate><volume>19</volume><issue>1</issue><spage>2168952</spage><epage>2168952</epage><pages>2168952-2168952</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><abstract>The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February 28, 2022, and on select public healthcare agency websites to identify and collect data from CE studies comparing RZV to zoster vaccine live (ZVL) or to no vaccination. Study characteristics, inputs, and outputs were collected. The overall CE of RZV was assessed. RZV vaccination against HZ is cost-effective in 15 out of 18 studies included in the present review. Varying incremental cost-effectiveness ratios (ICERs) observed may be associated with different assumptions on the duration of protection of RZV, as well as different combinations of structural and disease-related study (model) inputs driving the estimation of ICERs.
What is the context?
* Herpes zoster, also known as shingles, may cause painful rashes and skin alterations.
* Chronic pain, also referred to as post-herpetic neuralgia, may persist for months or even years after the initial rash.
* The disease is caused by reactivation of the varicella zoster virus.
* The recombinant zoster vaccine (RZV) and the zoster vaccine live (ZVL) are approved for the prevention of herpes zoster and post-herpetic neuralgia.
* We reviewed published evidence from the past 5 years on RZV.
What is new?
* Out of 18 selected studies, RZV vaccination against herpes zoster and post-herpetic neuralgia is cost-effective in 15.
* In the 15 studies establishing RZV cost-effectiveness, RZV is always cost-effective or frequently cost-saving in direct comparisons to ZVL, when applicable.
* RZV was found cost-saving in several immune-compromised populations.
What is the impact?
* The overview of the currently available body of evidence related to cost-effectiveness of RZV may help informing decision makers about the value of vaccination against herpes zoster.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>36916240</pmid><doi>10.1080/21645515.2023.2168952</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7423-0111</orcidid><orcidid>https://orcid.org/0000-0002-1707-2305</orcidid><orcidid>https://orcid.org/0000-0001-9130-4744</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2023-12, Vol.19 (1), p.2168952-2168952 |
| issn | 2164-5515 2164-554X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2786813548 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Alma/SFX Local Collection |
| subjects | Cost-Benefit Analysis cost-effectiveness Herpes zoster Herpes Zoster - prevention & control Herpes Zoster Vaccine Herpesvirus 3, Human Humans Licensed Vaccines – Review Neuralgia, Postherpetic - prevention & control older adults recombinant zoster vaccine Review Vaccination Vaccines, Synthetic |
| title | Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T10%3A19%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20the%20recombinant%20zoster%20vaccine%20(RZV)%20against%20herpes%20zoster:%20An%20updated%20critical%20review&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Giannelos,%20Nikolaos&rft.date=2023-12-31&rft.volume=19&rft.issue=1&rft.spage=2168952&rft.epage=2168952&rft.pages=2168952-2168952&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2023.2168952&rft_dat=%3Cproquest_infor%3E2786813548%3C/proquest_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2786813548&rft_id=info:pmid/36916240&rft_doaj_id=oai_doaj_org_article_04e618451d634eb090eea6c65e94dcbd&rfr_iscdi=true |